IRF2BPL : A new genotype for progressive myoclonus epilepsies
Epilepsia · 2023-08 · 64 (8)
DOI: 10.1111/epi.17557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, online erschienen am 09.03.2023. Verfasst von Cinzia Costa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Clinic, Department of Medicine and Surgery, University of Perugia-S. Maria Della Misericordia Hospital, Perugia, Italy. Hauptthemen laut MEDLINE: Myoclonic Epilepsies, Progressive, Epilepsies, Myoclonic, Movement Disorders. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Ministero della Salute, National Health and Medical Research Council.
Abstract (Originalsprache)
The progressive myoclonus epilepsies (PMEs) are a heterogeneous group of neurodegenerative disorders, typically presenting in late childhood. An etiologic diagnosis is achieved in about 80% of patients with PME, and genome‐wide molecular studies on remaining, well‐selected, undiagnosed cases can further dissect the underlying genetic heterogeneity. Through whole‐exome sequencing (WES), we identified pathogenic truncating variants in the IRF2BPL gene in two, unrelated patients presenting with PME. IRF2BPL belongs to the transcriptional regulators family and it is expressed in multiple human tissues, including the brain. Recently missense and nonsense mutations in IRF2BPL were found in patients presenting with developmental delay and epileptic encephalopathy, ataxia, and movement disorders, but none with clear PME. We identified 13 other patients in the literature with myoclonic seizures and IRF2BPL variants. There was no clear genotype–phenotype correlation. With the description of these cases, the IRF2BPL gene should be considered in the list of genes to be tested in the presence of PME, in addition to patients with neurodevelopmental or movement disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Clinic, Department of Medicine and Surgery, University of Perugia-S. Maria Della Misericordia Hospital, Perugia, Italy.
- Department of Medicine (Austin Health), Epilepsy Research Centre, University of Melbourne, Heidelberg, Victoria, Australia.
- Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
- Medical Genetics Unit, Maternal-Infantile Department, S. Maria della Misericordia Hospital, Perugia, Italy.
- Medical Genetics Unit, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
- R&I Genetics SRL, Padua, Italy.
ORCID-Profile: Karen L Oliver, Laura Canafoglia, Samuel F Berkovic, Paolo Prontera
Förderung
- Ministero della Salute
- National Health and Medical Research Council
Zitieren
APA
Costa, C., Oliver, K. L., Calvello, C., Cameron, J. M., Imperatore, V., Tonelli, L., Colavito, D., Franceschetti, S., Canafoglia, L., Berkovic, S. F., & Prontera, P. (2023). IRF2BPL : A new genotype for progressive myoclonus epilepsies. Epilepsia, 64(8). https://doi.org/10.1111/epi.17557
Vancouver
Costa C, Oliver KL, Calvello C, Cameron JM, Imperatore V, Tonelli L, et al. IRF2BPL : A new genotype for progressive myoclonus epilepsies. Epilepsia. 2023;64(8). doi:10.1111/epi.17557
BibTeX
@article{Costa2023,
author = {Costa, Cinzia and Oliver, Karen L and Calvello, Carmen and Cameron, Jillian M and Imperatore, Valentina and Tonelli, Laura and Colavito, Davide and Franceschetti, Silvana and Canafoglia, Laura and Berkovic, Samuel F and Prontera, Paolo},
title = {IRF2BPL : A new genotype for progressive myoclonus epilepsies},
journal = {Epilepsia},
year = {2023},
volume = {64},
number = {8},
doi = {10.1111/epi.17557}
}
EUVIMED